A
10.71
-0.51 (-4.55%)
| Previous Close | 11.22 |
| Open | 11.02 |
| Volume | 83,780 |
| Avg. Volume (3M) | 81,685 |
| Market Cap | 74,449,176 |
| Price / Sales | 25.19 |
| Price / Book | 0.700 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -6,187.46% |
| Diluted EPS (TTM) | -17.47 |
| Quarterly Revenue Growth (YOY) | -68.50% |
| Total Debt/Equity (MRQ) | 6.76% |
| Current Ratio (MRQ) | 7.56 |
| Operating Cash Flow (TTM) | -78.91 M |
| Levered Free Cash Flow (TTM) | -44.94 M |
| Return on Assets (TTM) | -38.74% |
| Return on Equity (TTM) | -60.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Aligos Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
0.1
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.13 |
|
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.44% |
| % Held by Institutions | 65.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Readystate Asset Management Lp | 30 Jun 2025 | 136,782 |
| 52 Weeks Range | ||
| Median | 50.00 (366.85%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Sep 2025 | 50.00 (366.85%) | Buy | 10.20 |
| 18 Aug 2025 | 50.00 (366.85%) | Buy | 8.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting |
| 02 Sep 2025 | Announcement | Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
| 20 Aug 2025 | Announcement | Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs |
| 13 Aug 2025 | Announcement | Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection |
| 06 Aug 2025 | Announcement | Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results |
| 30 Jul 2025 | Announcement | Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 |
| 18 Jun 2025 | Announcement | Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |